Agranulocyosis in Beta Thalassemia Major Patients treated with Oral Iron Chelating Agent (Deferiprone)

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)
6 Downloads (Pure)


Deferiprone is an oral chelating agent that has been recently shown to reduce cardiac siderosis, but is also known to be associated with serious side effects like agranulocytosis which can be fatal. This report is a single centre experience of 5 cases with severe agranulocytosis in amongst 144 patients (3.47%) of thalassemia major on combined chelation therapy with subcutaneous desferrioxamine and oral deferiprone which is much higher than the previous reports.

Original languageEnglish
Pages (from-to)275-277
Number of pages3
JournalOman Medical Journal
Issue number4
Publication statusPublished - Oct 2008


  • Deferiprone
  • Granulocytosis
  • Thalassemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this